{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:39:05Z","timestamp":1790217545632,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2024-MSLH-550"],"award-info":[{"award-number":["2024-MSLH-550"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218737","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:38:26Z","timestamp":1784129906000},"page":"218737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Membrane bionic supramolecular nanomaterials for co-delivered of ribociclib and PEG10 siRNA for targeted therapy in breast cancer"],"prefix":"10.1016","volume":"658","author":[{"given":"Yifan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218737_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"Britt","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218737_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2023.25881","article-title":"Analysis of breast cancer mortality in the US-1975 to 2019","volume":"331","author":"Caswell-Jin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2026.218737_bib3","year":"2024","journal-title":"Female Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218737_bib4","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1080\/09205063.2020.1764163","article-title":"Cancer cell membrane-coated biomimetic platform for targeted therapy of breast cancer in an orthotopic mouse model","volume":"31","author":"Han","year":"2020","journal-title":"J. Biomater. Sci."},{"key":"10.1016\/j.canlet.2026.218737_bib5","first-page":"23","article-title":"Novel tumor-targeting nanoparticles for cancer Treatment-A review","author":"Niculescu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218737_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijbiomac.2021.10.142","article-title":"Polysaccharide\/mesoporous silica nanoparticle-based drug delivery systems: a review","volume":"193","author":"Kuang","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.canlet.2026.218737_bib7","article-title":"Mesoporous silica materials as an emerging tool for cancer immunotherapy","volume":"9","author":"Escriche-Navarro","year":"2022","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.canlet.2026.218737_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.118822","article-title":"Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy","volume":"277","author":"Lohiya","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.canlet.2026.218737_bib9","doi-asserted-by":"crossref","first-page":"38323","DOI":"10.1021\/acsami.3c07541","article-title":"Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy","volume":"15","author":"Garrido-Cano","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218737_bib10","doi-asserted-by":"crossref","first-page":"23197","DOI":"10.1021\/acsami.5b07033","article-title":"Cyclodextrin-modified porous silicon nanoparticles for efficient sustained drug delivery and proliferation inhibition of breast cancer cells","volume":"7","author":"Correia","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218737_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111168","article-title":"Hydroxypropyl-\u03b2-cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity","volume":"125","author":"Zhu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218737_bib12","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1080\/09205063.2023.2208458","article-title":"Folate-mediated magnetic and pH\/GSH dual-responsive metal-polymer-coordinated nanocomplexes for joint chemo\/chemodynamic anti-breast cancer therapy","volume":"34","author":"Lan","year":"2023","journal-title":"J. Biomater. Sci."},{"key":"10.1016\/j.canlet.2026.218737_bib13","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.2147\/IJN.S369732","article-title":"A double-chamber \"Dandelion\" appearance sequential drug delivery system for synergistic treatment of malignant tumors","volume":"17","author":"Li","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218737_bib14","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218737_bib15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.canlet.2026.218737_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with Palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2026.218737_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218737_bib18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218737_bib19","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2022.5184","article-title":"CDK4\/6 inhibitor resistance mechanisms and treatment strategies","volume":"50","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218737_bib20","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1535-7163.MCT-19-1031","article-title":"Paternally expressed gene 10 (PEG10) promotes growth, invasion, and survival of bladder cancer","volume":"19","author":"Kawai","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218737_bib21","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1097\/DCR.0000000000001774","article-title":"Differential expression of PEG10 contributes to aggressive disease in early versus late-onset colorectal cancer","volume":"63","author":"Watson","year":"2020","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.canlet.2026.218737_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12935-018-0610-3","article-title":"PEG10 as an oncogene: expression regulatory mechanisms and role in tumor progression","volume":"18","author":"Xie","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2026.218737_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/cgt.2014.77","article-title":"Long noncoding RNA PEG10 regulates proliferation and invasion of esophageal cancer cells","volume":"22","author":"Zang","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2026.218737_bib24","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3892\/ijo.2016.3406","article-title":"PEG10 promotes human breast cancer cell proliferation, migration and invasion","volume":"48","author":"Li","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2026.218737_bib25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13046-023-02903-x","article-title":"Targeting PEG10 as a novel therapeutic approach to overcome CDK4\/6 inhibitor resistance in breast cancer","volume":"42","author":"Katuwal","year":"2023","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"key":"10.1016\/j.canlet.2026.218737_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijbiomac.2021.06.014","article-title":"Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies","volume":"184","author":"Helmi","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.canlet.2026.218737_bib27","first-page":"27","article-title":"Biomimetic targeted theranostic nanoparticles for breast cancer treatment","author":"Marshall","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.canlet.2026.218737_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112895","article-title":"Red blood cell membrane nanoparticles for tumor phototherapy","volume":"220","author":"Zheng","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.canlet.2026.218737_bib29","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.7150\/thno.61259","article-title":"A platelet-mimicking theranostic platform for cancer interstitial brachytherapy","volume":"11","author":"Lyu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218737_bib30","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1021\/acs.nanolett.7b05263","article-title":"Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.canlet.2026.218737_bib31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/1061186X.2023.2283838","article-title":"Recent advances in cancer cell bionic nanoparticles for tumour therapy","volume":"31","author":"Jiang","year":"2023","journal-title":"J. Drug Target."},{"key":"10.1016\/j.canlet.2026.218737_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121714","article-title":"Magnetic nanoparticle-based hyperthermia: a prospect in cancer stem cell tracking and therapy","volume":"323","author":"Montazersaheb","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2026.218737_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121449","article-title":"Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework","volume":"283","author":"Pan","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218737_bib34","doi-asserted-by":"crossref","first-page":"22820","DOI":"10.1021\/acsami.6c01140","article-title":"Research on therapeutic strategy of inhalable cell membrane-coated nanodelivery complexes mediating Nrf2 pathway for ameliorating pulmonary fibrosis","volume":"18","author":"Li","year":"2026","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218737_bib35","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1007\/s00216-019-01932-w","article-title":"Development and validation of a bioanalytical method for the quantification of the CDK4\/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry","volume":"411","author":"Mart\u00ednez-Ch\u00e1vez","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.canlet.2026.218737_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217750","article-title":"Anoikis resistance in cancer: mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding","volume":"624","author":"Shaw","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218737_bib37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4149\/gpb_2019018","article-title":"Knockdown long non-coding RNA PEG10 inhibits proliferation, migration and invasion of glioma cell line U251 by regulating miR-506","volume":"38","author":"Liang","year":"2019","journal-title":"Gen. Physiol. Biophys."},{"key":"10.1016\/j.canlet.2026.218737_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1378090","article-title":"CDK4\/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network","volume":"15","author":"She","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218737_bib39","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1186\/s12967-024-05828-x","article-title":"RERE-AS1 enhances the effect of CDK4\/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK\/ERK pathway","volume":"22","author":"Huang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218737_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218737_bib41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jksus.2018.08.005","article-title":"Synthesis and characterization of Chitosan\u2013silica hybrid aerogel using sol-gel method","volume":"32","author":"Ebisike","year":"2020","journal-title":"J. King Saud Univ. Sci."},{"key":"10.1016\/j.canlet.2026.218737_bib42","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1021\/acs.molpharmaceut.0c00488","article-title":"Influence of drug\u2013silica electrostatic interactions on drug release from mesoporous silica-based oral delivery systems","volume":"17","author":"Hate","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.canlet.2026.218737_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10856-021-06623-6","article-title":"In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes","volume":"32","author":"Barani","year":"2021","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.canlet.2026.218737_bib44","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1039\/D0SC01756F","article-title":"Supramolecular combination chemotherapy: a pH-responsive co-encapsulation drug delivery system","volume":"11","author":"Chen","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.canlet.2026.218737_bib45","first-page":"15","article-title":"pH-Responsive hollow mesoporous silica nanoparticles with fludarabine for cancer therapy","author":"Park","year":"2025","journal-title":"Nanomaterials (Basel, Switzerland)"},{"key":"10.1016\/j.canlet.2026.218737_bib46","doi-asserted-by":"crossref","first-page":"19740","DOI":"10.1021\/acsnano.3c03195","article-title":"Reactive oxygen species-sensitive biodegradable mesoporous silica nanoparticles harboring TheraVac elicit tumor-specific immunity for Colon tumor treatment","volume":"17","author":"Huang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218737_bib47","doi-asserted-by":"crossref","first-page":"38294","DOI":"10.1021\/acsami.3c06909","article-title":"pH-Sensitive biomimetic nanosystem based on large-pore mesoporous silica nanoparticles with high hyaluronidase loading for tumor deep penetration","volume":"15","author":"Song","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218737_bib48","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1002\/adma.201506086","article-title":"Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging","volume":"28","author":"Rao","year":"2016","journal-title":"Advanced materials (Deerfield Beach, Fla.)"},{"key":"10.1016\/j.canlet.2026.218737_bib49","article-title":"Cell membrane-coated nanomaterials for cancer therapy","volume":"20","author":"Zeng","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.canlet.2026.218737_bib50","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2147\/IJN.S266948","article-title":"Cancer cell-membrane biomimetic boron nitride nanospheres for targeted cancer therapy","volume":"16","author":"Feng","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218737_bib51","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1021\/acs.nanolett.9b03817","article-title":"Cancer-cell-membrane-coated nanoparticles with a yolk-shell structure augment cancer chemotherapy","volume":"20","author":"Nie","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.canlet.2026.218737_bib52","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2147\/IJN.S295565","article-title":"Cancer cell membrane camouflaged mesoporous silica nanoparticles combined with immune checkpoint blockade for regulating tumor microenvironment and enhancing antitumor therapy","volume":"16","author":"Zhao","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218737_bib53","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.7150\/thno.99260","article-title":"Macrophage membrane\u2012biomimetic nanoparticles target inflammatory microenvironment for epilepsy treatment","volume":"14","author":"Geng","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218737_bib54","article-title":"Trastuzumab-functionalized SK-BR-3 cell membrane-wrapped mesoporous silica nanoparticles loaded with pyrotinib for the targeted therapy of HER-2-positive breast cancer","volume":"8","author":"Liu","year":"2024","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.canlet.2026.218737_bib55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12964-023-01183-4","article-title":"Anoikis resistance--protagonists of breast cancer cells survive and metastasize after ECM detachment","volume":"21","author":"Dai","year":"2023","journal-title":"Cell Commun. Signal. : CCS"},{"key":"10.1016\/j.canlet.2026.218737_bib56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-023-01753-7","article-title":"Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination","volume":"22","author":"Huh","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218737_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218737_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"key":"10.1016\/j.canlet.2026.218737_bib59","article-title":"Enabling tumor-specific drug delivery by targeting the warburg effect of cancer","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218737_bib60","article-title":"Multifunctional beta-cyclodextrin-modified selenium hybrid hollow mesoporous silica nanospheres for mitochondrial targeted carbon monoxide delivery","volume":"21","author":"Zhou","year":"2025","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"key":"10.1016\/j.canlet.2026.218737_bib61","article-title":"Membrane-modified mesoporous silica nanoparticles guided by tumor immunomodulatory regulation for anti-tumor strategies","volume":"17","author":"Gao","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218737_bib62","doi-asserted-by":"crossref","DOI":"10.1007\/s10495-026-02340-z","article-title":"Celecoxib potentiates ribociclib-induced apoptosis and anti-tumor activity by co-targeting COX-2\/NF-\u03baB and PI3K\/AKT\/mTOR pathways in hormone receptor-positive\/HER2-negative breast cancer","volume":"31","author":"Han","year":"2026","journal-title":"Apoptosis : an international journal on programmed cell death"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600501X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600501X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:42:46Z","timestamp":1788482566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600501X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":62,"alternative-id":["S030438352600501X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218737","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Membrane bionic supramolecular nanomaterials for co-delivered of ribociclib and PEG10 siRNA for targeted therapy in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218737"}}